Drugs / ZN-d5
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05127811 | Oct 2021 → May 2023 | non-Hodgkin lymphoma | Zentera Therapeutics HK Limited | Terminated | No outcome recorded |
| Phase 1 | NCT04854174 | Jun 2021 | — | Zentalis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04500587 | Oct 2020 → Dec 2023 | acute myeloid leukemia, non-Hodgkin lymphoma | Zentalis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05682170 | Dec 2022 → Jul 2024 | acute myeloid leukemia | Zentalis Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05199337 | Nov 2021 → Feb 2024 | AL amyloidosis | Zentalis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-08-09 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Results Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results And Operational Progress zentalis.com ↗
The combination demonstrated clinical activity in patients who had been previously treated with venetoclax. |
| 2020-04-30 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Regulatory Zentalis Pharmaceuticals Announces Fda Clearance Of Ind Application For Zn-D5 For The Treatment Of Hematologic Malignancies zentalis.com ↗
ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-08-09 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results And Operational Progress zentalis.com ↗ |
| 2020-04-30 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Zentalis Pharmaceuticals Announces Fda Clearance Of Ind Application For Zn-D5 For The Treatment Of Hematologic Malignancies zentalis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZN-d5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05199337 ↗ |
| Action | Inhibit | “the novel BCL-2 inhibitor ZN-d5” NCT04500587 ↗ |
| Route | Oral | “Oral agent; 25 mg or 100 mg formulation” NCT04500587 ↗ |